Expanded Portfolio for Biomolecules Purification Announced
Oct 12 2017 Read 718 Times
With the increased interest in the purification of a wider variety of biomolecules, the portfolio of Kromasil 300 Å has been expanded to support these applications.
The Kromasil 300 Å line of HPLC products is now shipping with C18, C8, C4 and diC4 derivatisations for scientists and engineers exploiting selectivity and loadability for purification of API and impurity isolation. In particular, the new Kromasil 300 Å diC4 has different characteristic than a classic C4, enabling new opportunities to remove impurities from peptide and protein crudes.
For more information, visit www.kromasil.com
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Why Does Nanotechnology Require Mass Spectrometry Spotlight Features Luminescence, UV & Microplate Readers - New Confocal Laser Scanning Microscope Combine...
View all digital editions
Jul 29 2018 Chicago, IL, USA
Jul 29 2018 Washington DC, USA
Aug 05 2018 Baltimore, MD, USA
Aug 06 2018 Westminster, CO, USA
Aug 06 2018 Berlin, Germany